Add to my selection

RYDAPT

Medicine - Posted on Mar 04 2021

Active substance (DCI)

midostaurine

history (4)

2/17/21

RYDAPT (midostaurine)

Key points Favourable opinion for maintenance of reimbursement, as monotherapy, for the treatment of adult patients with agg...

CAV :
54321

icône flèche
6/27/18

RYDAPT (midostaurin), tyrosine kinase inhibitor

Low clinical benefit in the treatment of aggressive systemic mastocytosis (ASM), systemic mastocytosis associated with a sec...

CAV :
54321

icône flèche
6/13/18

RYDAPT (midostaurine), tyrosine kinase inhibitor

High clinical benefit in the treatment of newly diagnosed acute myeloid leukaemia with FLT3 gene mutation, combined with che...

CAV :
54321

icône flèche
10/3/18

RYDAPT (midostaurine)

Mise à disposition d’une présentation en boîte de 56 capsules en complément des boîtes de 112 capsules. ...

CAV :
54321

icône flèche

Technical information

ATC code

L01XE39

Manufacturer

NOVARTIS PHARMA S.A.S.

Presentation

RYDAPT 25 mg, capsule molle (code CIS : 67868413)
Conditionnements multiples de 56 (2 boîtes de 28) capsules sous plaquettes polyamide aluminium PVC-Aluminium (CIP : 34009 301 298 2 1)
Conditionnements multiples de 112 (4 boîtes de 28) capsule(s) sous plaquette(s) polyamide aluminium PVC (CIP : 34009 301 136 0 8)

All our publications

Blood and lymphatic diseases - miscellaneous